TRAP
Research type
Research Study
Full title
TRAP: Targeted Radiotherapy in Androgen-suppressed Prostate cancer patients
IRAS ID
236423
Contact name
Alison Tree
Contact email
Sponsor organisation
The Royal Marsden NHS Foundation Trust
Clinicaltrials.gov Identifier
Duration of Study in the UK
4 years, 0 months, 1 days
Research summary
The aim of the TRAP trial is to test whether a new precise radiotherapy technique called stereotactic body radiotherapy (SBRT) can slow down the growth of prostate cancer which has already spread. If SBRT is effective it will represent a new treatment option in these patients, providing more prolonged control without having to resort to chemotherapy and its potentially unpleasant side effects.
In this trial, we will identify men who, despite being on treatment (Abiraterone or Enzalutamide), have developed one or two new sites of worsening (growing) disease but the rest of their cancer is still responding to hormonal therapy. We believe SBRT can successfully treat the cancer which is resistant to current treatment which we hope means we can control their cancer for longer. We may be also able to use the tell-tale products (markers) they release into the bloodstream, or characteristics on novel imaging such as MRI, to help identify patients in the future who will benefit the most.
SBRT has been shown to be safe and effective in some patients with advanced cancer. The treatment is now widely available within England and we want to test if it's effective in a new setting. Standard treatment for metastatic prostate cancer is varying types of hormone therapy but eventually, most patients become resistant to this therapy and unfortunately their cancer gets worse. At this stage, we usually use chemotherapy which has unwanted side-effects and does not offer long-term control. We believe SBRT will be of benefit but it is likely that it will be more effective in some men than others, so we will use a combination of whole body MRI scans combined with genetic analysis of tiny fragments of cancer cells found in the bloodstream.
REC name
London - Chelsea Research Ethics Committee
REC reference
18/LO/0584
Date of REC Opinion
17 Apr 2018
REC opinion
Favourable Opinion